Sekorts Therapeutics - Rockville, Maryland 20850

Sekorts Therapeutics is categorized under in Rockville, MD .

Business Name: Sekorts Therapeutics
Contact Person: Gary Broker
Address: 13702 Safe Harbor Court, Rockville, Maryland 20850
Phone Number: (301) 704-7360
Annual Revenue (USD): $100.000 to $499.999
Founding Year: 2006
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2B & B2C
Business Category:
SIC Code: 2834
NAICS Code: 325412
Share This Business:
Related Businesses: Synthetic Biologics Inc - Rockville, MD 20850
Imaging Probe Development Center - Rockville, MD 20850
Botanical Enterprises Inc - Rockville, MD 20850
Celek Pharmaceuticals LLC - Rockville, MD 20850
Prometic Biothdrateutics Inc - Rockville, MD 20850
American Gene Technologies International Inc - Rockville, MD 20850
Glaxosmithkline LLC - Rockville, MD 20850
Entre Med Inc - Rockville, MD 20850
Chiesi Pharmaceuticals Inc - Rockville, MD 20850
Principia Pharmaceutical Corp - Rockville, MD 20850
Emergent Biosolutions Inc - Rockville, MD 20850
Supernus Pharmaceuticals Inc - Rockville, MD 20850
Regene Rx Biopharmaceuticals - Rockville, MD 20850
Tasly Pharmaceuticals Inc - Rockville, MD 20850
Ems Development Group LLC - Rockville, MD 20850
Sunascen Therapeutics LLC - Rockville, MD 20850
Sanofi Pasteur Biologics LLC - Rockville, MD 20850

The company Sekorts Therapeutics provides BOTH services in the form of from its single location in Maryland. 1 to 4 employees work for Sekorts Therapeutics, and the business now earns $100.000 to $499.999 per annum.

Sekorts Therapeutics was launched in 2006 and is classified under SIC code and category 2834 , and NAICS number and grouping 325412 . To contact Sekorts Therapeutics, please call Gary Broker with the phone number (301) 704-7360 or visit its single location at 13702 Safe Harbor Court in Rockville, Maryland 20850.

The location of the single location can also be found using the coordinates . Read more details about this business on the webpage or follow the company’s social media accounts, on Twitter and on Facebook.